ProfileGDS5678 / 1418262_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 83% 77% 76% 84% 81% 78% 80% 78% 81% 78% 81% 81% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9120482
GSM967853U87-EV human glioblastoma xenograft - Control 26.1515783
GSM967854U87-EV human glioblastoma xenograft - Control 35.2213777
GSM967855U87-EV human glioblastoma xenograft - Control 45.2432276
GSM967856U87-EV human glioblastoma xenograft - Control 56.2840384
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6691681
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2111578
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6421780
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.329678
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8888581
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3277578
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8402681
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7158781
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.8934682